TY - JOUR
T1 - Treatment of therapy-related leukemia and myelodysplastic syndrome
AU - Kantarjian, H. M.
AU - Estey, E. H.
AU - Keating, M. J.
PY - 1993
Y1 - 1993
N2 - The increasing incidence of therapy-related leukemia and myelodysplastic syndrome reflects (1) a longer period at risk resulting from successful treatment of solid tumors; (2) more intensive treatment regimens combining high-dose chemotherapy and irradiation; (3) broader utilization of adjuvant chemoirradiation in melanoma, colon, lung, breast, and head and neck cancers; and (4) environmental pollution and widespread exposure to chemicals and carcinogens in industrialized nations. The availability of novel therapies, including growth factors, has increased the referral of these patients to comprehensive cancer centers, partially explaining the increased awareness of the entity.
AB - The increasing incidence of therapy-related leukemia and myelodysplastic syndrome reflects (1) a longer period at risk resulting from successful treatment of solid tumors; (2) more intensive treatment regimens combining high-dose chemotherapy and irradiation; (3) broader utilization of adjuvant chemoirradiation in melanoma, colon, lung, breast, and head and neck cancers; and (4) environmental pollution and widespread exposure to chemicals and carcinogens in industrialized nations. The availability of novel therapies, including growth factors, has increased the referral of these patients to comprehensive cancer centers, partially explaining the increased awareness of the entity.
UR - http://www.scopus.com/inward/record.url?scp=0027520983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027520983&partnerID=8YFLogxK
U2 - 10.1016/s0889-8588(18)30259-4
DO - 10.1016/s0889-8588(18)30259-4
M3 - Review article
C2 - 7680643
AN - SCOPUS:0027520983
SN - 0889-8588
VL - 7
SP - 81
EP - 107
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 1
ER -